Patisiran sodiumProduct ingredient for Patisiran

Name
Patisiran sodium
Drug Entry
Patisiran

Parisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis 4. It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.

Accession Number
DBSALT002783
Structure
Synonyms
Not Available
UNII
WO0YM16LKG
CAS Number
1386913-72-9
Not Available
Predicted Properties
Not Available